Paola Ulivi

List of Publications by Year
in descending order

74	2,327	212478 28	263392 45
papers	citations	h-index	g-index

76	76	76	4819
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics, 2022, 14, 507-517.	1.0	4
2	Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations. Translational Oncology, 2022, 23, 101471.	1.7	3
3	Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Translational Lung Cancer Research, 2021, 10, 1525-1535.	1.3	11
4	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 669839.	1.3	4
5	Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications. Journal of Dermatological Treatment, 2020, , 1-8.	1.1	2
6	Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	3.2	13
7	Predictive biomarkers in clinical practice: State of the art and perspectives in solid tumors. International Journal of Biological Markers, 2020, 35, 16-19.	0.7	0
8	CDKN1A upregulation and cisplatinâ€'pemetrexed resistance in nonâ€'small cell lung cancer cells. International Journal of Oncology, 2020, 56, 1574-1584.	1.4	19
9	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 2019, 11, 1023.	1.7	23
10	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. Journal of Oncology, 2019, 2019, 1-11.	0.6	19
11	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.3	22
12	Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal CancerÂ(ITACa) study . Cancer Management and Research, 2019, Volume 11, 4357-4369.	0.9	17
13	Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. EBioMedicine, 2019, 43, 114-126.	2.7	40
14	Targeting RET-rearranged non-small-cell lung cancer: future prospects . Lung Cancer: Targets and Therapy, 2019, Volume 10, 27-36.	1.3	40
15	New generation anaplastic lymphoma kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S280-S289.	1.3	14
16	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. World Journal of Gastroenterology, 2018, 24, 4152-4163.	1.4	134
17	Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). Journal of Thoracic Disease, 2018, 10, 4858-4864.	0.6	2
18	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. International Journal of Molecular Sciences, 2018, 19, 3733.	1.8	147

#	Article	IF	Citations
19	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Scientific Reports, 2017, 7, 1293.	1.6	21
20	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. International Journal of Molecular Sciences, 2017, 18, 1240.	1.8	38
21	Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. International Journal of Molecular Sciences, 2016, 17, 1186.	1.8	20
22	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer, 2016, 16, 429.	1.1	28
23	No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Scientific Reports, 2016, 6, 37621.	1.6	7
24	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clinical Lung Cancer, 2016, 17, 384-390.	1.1	77
25	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1Î±â€"Final results of the ALICE-2 study.. Journal of Clinical Oncology, 2016, 34, 280-280.	0.8	13
26	eNOSpolymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget, 2016, 7, 27988-27999.	0.8	30
27	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget, 2016, 7, 46678-46691.	0.8	35
28	Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0134732.	1.1	37
29	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. Journal of Translational Medicine, 2015, 13, 258.	1.8	33
30	EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. Oncology Letters, 2015, 9, 1432-1438.	0.8	3
31	Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?. International Journal of Molecular Sciences, 2015, 16, 747-757.	1.8	28
32	111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer. Nuclear Medicine Communications, 2015, 36, 135-142.	0.5	1
33	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	0.9	66
34	EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?. PLoS ONE, 2014, 9, e85388.	1.1	35
35	KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC). PLoS ONE, 2014, 9, e92071.	1.1	52
36	Discrepancies between VEGF â^'1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue. International Journal of Molecular Sciences, 2014, 15, 13333-13343.	1.8	10

#	Article	IF	Citations
37	Efficacy of Different Sequences of Radioâ€•and Chemotherapy in Experimental Models of Human Melanoma. Journal of Cellular Physiology, 2014, 229, 1548-1556.	2.0	8
38	miRNAs as Non-Invasive Biomarkers for Lung Cancer Diagnosis. Molecules, 2014, 19, 8220-8237.	1.7	51
39	SLUG silencing increases radiosensitivity of melanoma cells in vitro. Cellular Oncology (Dordrecht), 2013, 36, 131-139.	2.1	18
40	Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cellular Oncology (Dordrecht), 2013, 36, 439-448.	2.1	36
41	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Letters, 2013, 335, 225-231.	3.2	208
42	Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. International Journal of Molecular Sciences, 2013, 14, 10332-10342.	1.8	72
43	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. Molecular and Clinical Oncology, 2013, 1, 575-581.	0.4	42
44	MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study. International Journal of Molecular Sciences, 2013, 14, 24097-24112.	1.8	11
45	Molecular determinations ofEGFRandEML4-ALKon a single slide of NSCLC tissue. Journal of Clinical Pathology, 2013, 66, 708-710.	1.0	11
46	Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis. PLoS ONE, 2013, 8, e57401.	1.1	64
47	EGFRandK-rasmutations in cytologic samples from fine-needle aspirates in NSCLC patients: Table 1â€“. European Respiratory Journal, 2012, 40, 267-269.	3.1	13
48	Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. International Journal of Oncology, 2012, 41, 147-52.	1.4	15
49	Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell International, 2012, 12, 48.	1.8	19
50	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study. Journal of Translational Medicine, 2012, 10, 87.	1.8	37
51	Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. Journal of Cellular Physiology, 2012, 227, 3389-3396.	2.0	24
52	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of Cellular and Molecular Medicine, 2011, 15, 316-326.	1.6	5
53	Activity of different anthracycline formulations in hormoneâ€refractory prostate cancer cell lines: Role of golgi apparatus. Journal of Cellular Physiology, 2011, 226, 3035-3042.	2.0	7
54	Increased Levels of Free Circulating Dna in Patients with Idiopathic Pulmonary Fibrosis. International Journal of Biological Markers, 2010, 25, 229-235.	0.7	26

#	Article	IF	Citations
55	Docetaxelâ€“ST1481 sequence exerts a potent cytotoxic activity on hormoneâ€resistant prostate cancer cells by reducing drug resistanceâ€related gene expression. Prostate, 2010, 70, 219-227.	1.2	10
56	Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. Current Cancer Drug Targets, 2010, 10, 422-431.	0.8	19
57	Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. International Journal of Biological Markers, 2010, 25, 229-35.	0.7	14
58	Role of RAF/MEK/ERK pathway, pâ€STATâ€3 and Mclâ€1 in sorafenib activity in human pancreatic cancer cell lines. Journal of Cellular Physiology, 2009, 220, 214-221.	2.0	69
59	Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anti-Cancer Drugs, 2009, 20, 918-925.	0.7	12
60	Mitotic catastrophe and apoptosis induced by docetaxel in hormoneâ€refractory prostate cancer cells. Journal of Cellular Physiology, 2008, 217, 494-501.	2.0	51
61	Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. Journal of Translational Medicine, 2008, 6, 43.	1.8	24
62	Activity of lipoplatin in tumor and in normal cells in vitro. Anti-Cancer Drugs, 2008, 19, 983-990.	0.7	20
63	Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. Journal of Translational Medicine, 2007, 5, 52.	1.8	19
64	Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. Journal of Cellular Physiology, 2007, 212, 710-716.	2.0	11
65	Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine. Analytical Cellular Pathology, 2007, 29, 279-287.	0.7	15
66	Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines*. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1321-1330.	2.2	33
67	p16INK4A andCDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. Journal of Cellular Physiology, 2006, 206, 611-615.	2.0	66
68	Efficacy of a nitric oxideâ€releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Molecular Cancer Therapeutics, 2006, 5, 919-926.	1.9	43
69	Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models. Neoplasia, 2005, 7, 152-161.	2.3	16
70	In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. Journal of Translational Medicine, 2005, 3, 7.	1.8	33
71	Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Research, 2005, 7, R681-9.	2.2	63
72	Schedule-Dependent Cytotoxic Interaction between Epidoxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro. Clinical Cancer Research, 2004, 10, 1500-1507.	3.2	25

#	Article	IF	Citations
73	c-kit and SCF Expression in Normal and Tumor Breast Tissue. Breast Cancer Research and Treatment, 2004, 83, 33-42.	1.1	61
74	NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. International Journal of Oncology, 2003, 22, 1297-302.	1.4	6